GlassScriptPhysician profile
Joseph M Dyer
NPI 1932545019
$10,036.19
in general payments reported to CMS, 2019-2025
28 companies · $2,378 in 2025
The $2,378 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $307 · 2021: $670 · 2022: $1,396 · 2023: $1,924 · 2024: $2,637 · 2025: $2,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,566 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,566.00 |
| Education | $372.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,376.36 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $1,205.40 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,033.92 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,004.58 | 2019-2025 | |
| Janssen Biotech, INC. | $887.47 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $554.03 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $553.36 | 2022-2025 | |
| Lilly USA, LLC | $465.92 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $394.50 | 2021-2025 | Winlevi, Odomzo, Blu-U |
| Incyte Corporation | $379.66 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $369.60 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $292.87 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $274.75 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $233.45 | 2019-2025 | Nemluvio, Aklief |
| Ucb, INC. | $199.99 | 2022-2025 | Bimzelx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $151.90 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $143.71 | 2021-2024 | |
| Almirall LLC | $135.60 | 2019-2025 | Seysara |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.49 | 2022-2024 | Siliq, Targretin, Duobrii |
| Biofrontera INC. | $59.42 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boston Scientific Corporation | $28.92 | 2025 | General - Pain Management |
| Tempus Ai, INC | $24.97 | 2024 | Merlin Test |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.37 | 2025 | Spevigo |
| Botanix Sb INC | $19.57 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $18.37 | 2025 | Ycanth |
| Organon LLC | $17.84 | 2025 | Vtama |
| Fresenius Kabi USA, LLC | $17.18 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.